STAAR Surgical (STAA) versus National Vision (EYE) Critical Survey

STAAR Surgical (NASDAQ: STAA) and National Vision (NASDAQ:EYE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership and earnings.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a summary of recent recommendations and price targets for STAAR Surgical and National Vision, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STAAR Surgical 0 0 2 0 3.00
National Vision 0 3 5 0 2.63

STAAR Surgical presently has a consensus target price of $20.50, indicating a potential upside of 44.37%. National Vision has a consensus target price of $35.50, indicating a potential upside of 8.33%. Given STAAR Surgical’s stronger consensus rating and higher probable upside, analysts clearly believe STAAR Surgical is more favorable than National Vision.

Valuation & Earnings

This table compares STAAR Surgical and National Vision’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
STAAR Surgical $90.61 million 6.49 -$2.13 million $0.01 1,420.00
National Vision $1.38 billion 1.78 $45.82 million $0.53 61.83

National Vision has higher revenue and earnings than STAAR Surgical. National Vision is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

79.0% of STAAR Surgical shares are held by institutional investors. Comparatively, 97.4% of National Vision shares are held by institutional investors. 3.4% of STAAR Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares STAAR Surgical and National Vision’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
STAAR Surgical -2.36% -2.28% -1.34%
National Vision N/A N/A N/A

Summary

National Vision beats STAAR Surgical on 8 of the 13 factors compared between the two stocks.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.

National Vision Company Profile

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer primarily in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses under the America's Best, Eyeglass World, Walmart Vision Center, Vista Optical Fred Meyer, and Vista Optical Military brand stores, as well as provides optometric services. As of December 30, 2017, the company operated 1,013 retail stores across 5 brands, as well as 18 consumer Websites. National Vision Holdings, Inc. was founded in 1990 and is based in Duluth, Georgia.

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply